1. Home
  2. PDSB vs KYNB Comparison

PDSB vs KYNB Comparison

Compare PDSB & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$1.29

Market Cap

29.6M

Sector

Health Care

ML Signal

HOLD

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$6.91

Market Cap

31.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PDSB
KYNB
Founded
2005
1993
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.6M
31.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PDSB
KYNB
Price
$1.29
$6.91
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
932.3K
6.5K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
28.16
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.15
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$6.32
52 Week High
$1.90
$9.58

Technical Indicators

Market Signals
Indicator
PDSB
KYNB
Relative Strength Index (RSI) 65.91 44.72
Support Level $0.85 $6.67
Resistance Level $1.40 $7.42
Average True Range (ATR) 0.14 0.17
MACD 0.01 -0.02
Stochastic Oscillator 91.83 11.72

Price Performance

Historical Comparison
PDSB
KYNB

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: